Kurt C. Graves
Chairman
Mr. Graves is a global industry leader with more than 20 years of U.S. and global general management experience in top-tier U.S. and Europe-based pharmaceutical and biotechnology companies. He most recently served as Executive Vice President, Chief Commercial Officer, and Head of Strategic Development at Vertex Pharmaceuticals, where he led the development of the company's HCV and cystic fibrosis programs as well as the acquisition of Virochem Pharmaceuticals. Prior to joining Vertex, Mr. Graves held various leadership positions at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business Unit, a $15 billion business with eight therapeutic-area franchises; and he was the first Chief Marketing Officer for the Pharmaceuticals division. Prior to joining Novartis, Mr. Graves held various commercial and general management positions at Merck and Astra/Merck Pharmaceuticals, including U.S. GI Business Unit Head, with responsibility for developing and commercializing Prilosec® and Nexium® as well as the Prilosec OTC alliance with Procter & Gamble. Mr. Graves is Executive Chairman of Intarcia Therapeutics, Executive Chairman of Biolex Therapeutics, and a director of Pulmatrix Therapeutics and Springleaf Therapeutics. He holds a BS in Biology from Hillsdale College.

Alan H. Auerbach
Mr. Auerbach is the Founder, President, and CEO of Puma Biotechnology, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Previously, he founded Cougar Biotechnology and served as the company's President and CEO until the company's acquisition by Johnson & Johnson in 2009. Following the acquisition, Mr. Auerbach served as the Co-Chairman of the Integration Steering Committee at Cougar that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate, for the treatment of advanced prostate cancer. Prior to founding Cougar, Mr. Auerbach was a Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on oncology. He had primary responsibility for technical, scientific, and clinical due diligence as well as selection of biotechnology companies followed by the company. Prior to that, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, where he was responsible for research coverage of small-capitalization biotechnology companies. Previous to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. Mr. Auerbach received a BS in Biomedical Engineering from Boston University and an MS in Biomedical Engineering from the University of Southern California.

Jonathan Fleming
Mr. Fleming is the Managing General Partner of Oxford Bioscience Partners (OBP), an international venture capital firm specializing in life science technology-based investments. Mr. Fleming has been in the investment business for more than 20 years and has launched and financed growth companies in the United States, Europe, and Israel. Prior to joining OBP, Mr. Fleming was a Founding General Partner of MVP Ventures in Boston. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming is also a co-founder of Medica Venture Partners, a venture capital investment firm specializing in early-stage healthcare and biotechnology companies in Israel. Mr. Fleming is on the board of Asterand and is a director of several private companies including Leerink Swann, a Boston-based investment bank specializing in healthcare companies; Laboratory Partners, a clinical diagnostic testing company; and Railrunner, a rail products and services company. Mr. Fleming is a Trustee of the Museum of Science in Boston, a Member of the Board of the New England Healthcare Institute, and a Senior Lecturer at the MIT Sloan School of Business. He holds an MPA from Princeton University and a BA from the University of California, Berkeley.

Ansbert K. Gadicke, MD
Dr. Gadicke is a Co-Founder and Managing Director of MPM Capital. He led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. He received an MD from J.W. Goethe University in Frankfurt and subsequently held research positions in Biochemistry and Molecular Biology at the Whitehead Institute at MIT, Harvard University, and the German Cancer Research Center. He has published in leading scientific publications, including Nature and Cell. Dr. Gadicke is also a Director of Cerimon Pharmaceuticals; Dragonfly Sciences; Solasia Pharma K.K., Tokyo; and Verastem. He previously served as a Director of Arriva Pharmaceuticals, BioMarin, Biovitrum, Chiasma, Coelacanth, Idenix, Kourion, MediGene, Omrix Biopharmaceuticals, Pharmasset, PharmAthene, Transform, Xanodyne Pharmaceuticals, and ViaCell. He is a member of the Board of Fellows of Harvard Medical School.

Martin Münchbach, PhD
Dr. Münchbach is Managing Director of BB Biotech Ventures. Previously, he was Partner at BioMedinvest and Investment Advisor at HBM Partners. At BioMedinvest, he led several of the firm's investments and served on the board of portfolio companies. Before the merger of HBM Bioventures and NMT New Medical Technologies, he was Investment Manager at NMT, where he focused on international private equity investments in biopharmaceutical and biotechnology companies. Prior to his investment career, Dr. Münchbach gained experience in strategic marketing at Sanofi-Synthelabo. Dr. Münchbach also serves as a director of BioVascular, Molecular Partners AG, Optimer Pharmaceuticals, and Tioga Pharmaceuticals, Inc. He holds a PhD in Protein Chemistry, an MSc in Biochemistry, and a Master in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH), Zurich.

Elizabeth Stoner, MD
Dr. Stoner is a Managing Director at MPM Capital. An industry veteran with broad expertise in clinical research and pharmaceutical product development, Dr. Stoner joined MPM following a 22-year career at Merck Research Laboratories, where she served most recently as a Senior Vice President of Global Clinical Development Operations, with responsibility for Merck's clinical development activities in more than 40 countries. Dr. Stoner also oversaw the clinical development activities of Merck's Japanese partner, Banyu, led clinical development for the Merck/Schering-Plough Joint Venture for Zetia/Vytorin, and played a critical leadership role in Merck's efforts to transform its worldwide clinical development operations. Earlier in her career at Merck, she led the Proscar clinical development program from inception to establishing Merck as a leader in the field of prostate disease. As the Endocrine Therapeutic Head, Dr. Stoner's responsibilities included steroid and lipid metabolism, as well as the growth hormone secretagogue clinical research programs. Prior to her tenure at Merck, Dr. Stoner served as an Assistant Professor of Pediatrics at Cornell University Medical College. Dr. Stoner also serves as a director for Momenta Pharmaceuticals and is a member of the Scientific Advisory Board at Solasia. She received an MD from Albert Einstein College of Medicine, an MS in Chemistry from the State University of New York at Stony Brook, and a BS in Chemistry from Ottawa University, Kansas.

Michael S. Wyzga
Mr. Wyzga is President and Chief Executive Officer of Radius. Prior to joining Radius, he was Executive Vice President, Finance and Chief Financial Officer of Genzyme until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the firm's financial management worldwide. He provided key leadership in the successful $20.1 billion sale of Genzyme to Sanofi, which was the second-largest acquisition in biotechnology history, following Roche's $46.8 billion purchase of Genentech in 2009. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.